Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Nov 7, 2008; 14(41): 6401-6407
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401
Published online Nov 7, 2008. doi: 10.3748/wjg.14.6401
Table 1 The sequences of primers and probes
| Primers or probes | Sequences (5'-3') | Length ofproduct (bp) |
| actin-U | AGAAGATGACCCAGATCATGTT | 290 |
| actin-L | CTTAATGTCACGCACGATTTCC | |
| ERCC1-U | TACCACAACCTGCACCCAGACTAC | 321 |
| ERCC1-L | CTGACTGTCCGTTTTGTTGACTGA | |
| ERCC1-118-U | GGTCATCCCTATTGATGGCTTCTG | 154 |
| ERCC1-118-L | AGCTCACCTGAGGAACAGGGCACAG | |
| ERCC1-118-P | p-TTGCGCACGAACTTCAGTACGGGAT | |
| GGGACACTAATCGGAGGATTA-FAM | ||
| ERCC1-118-T | CTACGGAG GATTATGAGGAGCTGCGT | 92 |
| CGCCAAATTCCCAGGGCACA | ||
| ERCC1-118-C | CTACGAAATCAGGAGGATTATGAGGA | 97 |
| GACGTCGCCAAATTCCCAGGG CACG |
Table 2 Relationship among ERCC1 genotypes, mRNA expression and clinical characteristics of gastric cancer
| Clinical characteristics | n | ERCC1 polymorphism | χ2 | P | ERCC1 mRNA | χ2 | P | ||
| C/C (n = 45) | C/T + T/T (n = 44) | High value (n = 31) | Low value (n = 31) | ||||||
| Age (yr) | |||||||||
| ≥ 58 | 48 | 25 | 23 | 0.096 | 0.833 | 18 | 18 | 0 | 1.000 |
| < 58 | 41 | 20 | 21 | 13 | 13 | ||||
| Gender | |||||||||
| Male | 66 | 31 | 35 | 1.318 | 0.334 | 20 | 24 | 0.253 | 0.402 |
| Female | 23 | 14 | 9 | 11 | 7 | ||||
| TNM stage | |||||||||
| I-II | 19 | 13 | 6 | 3.082 | 0.079 | 6 | 6 | 0 | 1.000 |
| III-IV | 70 | 31 | 39 | 25 | 25 | ||||
| Grading | |||||||||
| G2 | 45 | 20 | 24 | 0.552 | 0.527 | 15 | 19 | 1.042 | 0.444 |
| G3 | 44 | 21 | 20 | 16 | 12 | ||||
-
Citation: Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, Song MX, Zhou XK.
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol 2008; 14(41): 6401-6407 - URL: https://www.wjgnet.com/1007-9327/full/v14/i41/6401.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.6401